Menu Search
Equities

Meditera Tibbi Malzeme Sanayi ve Ticaret AS

MEDTR.E:IST

Meditera Tibbi Malzeme Sanayi ve Ticaret AS

Actions
Health CareMedical Equipment and Services
  • Price (TRY)39.60
  • Today's Change1.10 / 2.86%
  • Shares traded796.94k
  • 1 Year change+12.50%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TRYIncome statement in TRYView more

Year on year Meditera Tibbi Malzeme Sanayi ve Ticaret AS's revenues fell -8.99% from 1.60bn to 1.45bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 114.34m to 25.87m, a -77.38% decrease.
Gross margin43.22%
Net profit margin-0.92%
Operating margin18.13%
Return on assets-0.90%
Return on equity-1.18%
Return on investment-1.07%
More ▼

Cash flow in TRYView more

In 2023, cash reserves at Meditera Tibbi Malzeme Sanayi ve Ticaret AS fell by 11.08m. However, the company earned 139.94m from its operations for a Cash Flow Margin of 9.64%. In addition the company used 1.69m on investing activities and also paid 149.33m in financing cash flows.
Cash flow per share0.4689
Price/Cash flow per share82.11
Book value per share14.58
Tangible book value per share14.57
More ▼

Balance sheet in TRYView more

Meditera Tibbi Malzeme Sanayi ve Ticaret AS uses little debt in its capital structure as supported by a debt to capital ratio of 4.23%.
Current ratio3.75
Quick ratio2.60
Total debt/total equity0.0443
Total debt/total capital0.0423
More ▼

Growth rates in TRY

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -76.67% and -77.38%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)2.44%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)15.68
EPS (TTM) vs
TTM 1 year ago		-129.94
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.